123O Randomized phase II trial of neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in early HER2-positive breast cancer (ABCSG-52/ATHENE)

表阿霉素 医学 帕妥珠单抗 曲妥珠单抗 内科学 阿替唑单抗 肿瘤科 乳腺癌 养生 化疗 胃肠病学 癌症 彭布罗利珠单抗 免疫疗法
作者
Gabriel Rinnerthaler,Daniel Egle,Rupert Bartsch,Clemens A. Schmitt,Andreas Petzer,Marija Balić,Edgar Petru,Ursula Denison,Christian F. Singer,Vesna Bjelic‐Radisic,Simon P. Gampenrieder,Michael Knauer,Florian Posch,Dominik Hlauschek,Lidija Sölkner,Zsuzsanna Bagó-Horváth,Martin Filipits,M. Lluïsa Gili,M.I. Gnant,Richard Greil
出处
期刊:ESMO open [Elsevier BV]
卷期号:8 (1): 101462-101462 被引量:1
标识
DOI:10.1016/j.esmoop.2023.101462
摘要

For most HER2-positive early breast cancer (EBC) patients (pts), neoadjuvant dual HER2 blockade with trastuzumab (T) and pertuzumab (P) plus poly-chemotherapy is standard of care. To improve the balance between toxicity burden and treatment outcomes, chemotherapy de-escalation has been a major focus in recent years. Among other immunogenic properties, anthracyclines can trigger an immunogenic cell death that engages the adaptive immune system. Within the ABCSG-52 trial we investigated a chemotherapy de-escalation immunotherapy regimen in HER2-positive EBC. Pts with previously untreated, histologically confirmed HER2-positive EBC (clinical prognostic stage cT1c-4a-d, N0–3,M0) were randomized 1:1 to two 3-weekly cycles of a chemotherapy-free induction phase (part 1) with TP plus 1200mg atezolizumab (TP+A) or TP alone. Afterwards, all pts received 4 cycles of TP+A in combination with epirubicin (part 2). The primary endpoint was pathological complete response (pCR; ypT0/Tis ypN0) in the overall study population. A pCR rate of ≥ 40% was considered as a positive trial result. Overall, 58 pts were randomized to TP-A (n=29) or TP (n=29) in 9 Austrian study centers. Median age was 57 (range 33-82), 16 pts (27.6%) had hormone-receptor (HR)-negative and 42 (72.4%) had HR-positive tumors. 45 pts (77.6%) had stage ≤ IIA and 13 (22.4%) ≥ IIB. In 35 pts a pCR was observed (60.3%; 95%CI 47.5% - 71.9%), 19 (65.5%) in the TP-A group and 16 (55.2%) in TP group (Δ 10.3%; 95%CI -14.7% - 35.4%). Residual cancer burden (RCB) class 0 or I was seen in 44 out of 55 pts (80%) with valid RCB assessment. Treatment emergent adverse events (AEs) grade ≥ 3 were reported in 17 pts (29.3%), 9 in TP-A group (31.0%) and 8 (27.6%) in TP group. No AEs of special interest (immune-related AEs, cardiac disorders grade ≥ 2, or infusion-related reactions) grade ≥ 3 were detected. Outcome according to PD-L1 expression status is currently analyzed and will also be presented at the meeting. For HER2-positive EBC, a neoadjuvant chemotherapy de-escalation immunotherapy regimen with trastuzumab, pertuzumab, atezolizumab and epirubicin is highly effective and safe and merits further investigation.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
量子星尘发布了新的文献求助10
1秒前
1秒前
英姑应助林汐采纳,获得10
1秒前
彤光赫显完成签到,获得积分10
1秒前
范东辉发布了新的文献求助10
2秒前
zy完成签到,获得积分10
2秒前
wang发布了新的文献求助10
2秒前
唧唧发布了新的文献求助10
2秒前
3秒前
研友_Z1WrgL完成签到,获得积分10
4秒前
4秒前
yimu完成签到,获得积分10
5秒前
5秒前
DH完成签到,获得积分10
5秒前
美好越彬发布了新的文献求助10
5秒前
香蕉觅云应助jl采纳,获得10
6秒前
sunly发布了新的文献求助10
6秒前
怡然的幻灵完成签到,获得积分10
6秒前
6秒前
fj发布了新的文献求助10
6秒前
大模型应助阿来哈哈采纳,获得10
6秒前
JAMESZHANGRY完成签到,获得积分20
7秒前
Minguk完成签到,获得积分10
7秒前
iOhyeye23完成签到 ,获得积分10
7秒前
Yuan应助鲁大师采纳,获得10
7秒前
7秒前
9秒前
桐桐应助nini采纳,获得20
9秒前
瘦瘦小萱完成签到 ,获得积分10
10秒前
10秒前
Akim应助Ai_niyou采纳,获得10
10秒前
10秒前
11秒前
12秒前
归尘发布了新的文献求助10
12秒前
bai完成签到,获得积分10
12秒前
MinMinma发布了新的文献求助10
13秒前
14秒前
14秒前
15秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3974358
求助须知:如何正确求助?哪些是违规求助? 3518706
关于积分的说明 11195521
捐赠科研通 3254897
什么是DOI,文献DOI怎么找? 1797614
邀请新用户注册赠送积分活动 877011
科研通“疑难数据库(出版商)”最低求助积分说明 806128